Aptus Pharma was incorporated on August 12, 2010. The company is engaged in marketing and distribution of finished pharmaceutical formulations through a contract manufacturing model. With agreements across seven manufacturing units, it offers a wide range of products across multiple therapeutic categories in diverse dosage forms
| Bidding Dates |
|---|
| 23 Sep 2025 - 25 Sep 2025 |
| Subscription |
|---|
| 20.82x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹2,60,000 | 2 | 2 | 2000 | 1.9 M | ₹65 - ₹70 | 72.89 % | ₹120.9 M - ₹130.2 M | RHP DOC |
Aptus Pharma IPO SUBSCRIPTION STATUS
25 Sep '25Aptus Pharma IPO overall subscription rate was 20.82 times the total available shares
Aptus Pharma IPO retail subscription rate was 41.94 times in the retail segment
Aptus Pharma IPO non-institutional investor subscription rate was 38.75 times in the non-institutional investor category
Aptus Pharma IPO Qualified Institutional Bidder subscription rate was 0.65 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
- | - | - | - |
25 Sep 2025 (Day 4) | 41.94x | 38.75x | 0.65x |
24 Sep 2025 (Day 3) | 7.28x | 8.67x | 0.43x |
23 Sep 2025 (Day 2) | 2.36x | 6.37x | 0x |
Aptus Pharma FINANCIALS
| Period | Revenue from Operations (Rs in crore) | Net Profit (Rs in crore) | Cash Flow from Operations (Rs in crore) | Free Cash Flow (Rs in crore) | Margins |
| FY25 | 24.6 | 3.1 | -1.8 | -2.5 | 19.3% |
| FY24 | 17.9 | 0.8 | -2.2 | -2.5 | 8.4% |
| FY23 | 13.9 | 0.2 | -0.2 | -0.5 | 4.1% |
Aptus Pharma IPO SUBSCRIPTION STATUS DETAILS
Aptus Pharma had 1.9 M shares on offer
Aptus Pharma IPO offer price was in the range ₹65 - ₹70
Aptus Pharma IPO minimum Investment was ₹260000
Aptus Pharma IPO issue size was ₹ 120.9 M - ₹ 130.2 M
Aptus Pharma had a minimum lot size of 2000 Shares per application
Aptus Pharma NUMBER OF SHARES ON OFFER
Aptus Pharma IPO IMPORTANT DATES
| Issue Open Date | 23 Sep 2025 |
| Issue close Date | 25 Sep 2025 |
| Allotment Date | 26 Sep 2025 |
| Refund Date | 29 Sep 2025 |
| Demat Account Credit Date | 29 Sep 2025 |
| Listing Date | 30 Sep 2025 |
| Listing on Exchange(s) | BSE |
| Aptus Pharma Allotment Status | Exchange/ Registrar |
Aptus Pharma IPO subscription opened on 23 Sep 2025, and closed on 25 Sep 2025
IPO allotment for Aptus Pharma was finalized on Friday, 26 Sep 2025
IPO listing for Aptus Pharma was on BSE on Tuesday, 30 Sep 2025
Aptus Pharma IPO LISTING GAINS
| Issue Price (adjusted) | 28.0 |
| Listing Open Price | 80.8 |
| Listing Close Price | 84.8 |
| Listing Gain% | 15.4% |
| Current Gain% | 840.9% |
Aptus Pharma Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aptus Pharma Ltd. | 263.4 | 180.7 | 97.8 | -2.4 | 3.9 | 19.8 | 10.6 | 46.7 | 89.6 | 4.6 | 49 | 2.7 | -40.4 |
| Sun Pharmaceutical Industries Ltd. | 1932.3 | 463623.5 | 38.3 | 2.3 | 7.7 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8537 | 226630.5 | 77.5 | 2.9 | 20.2 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4846.5 | 184345.3 | 84.5 | 9.5 | 11.7 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Zydus Lifesciences Ltd. | 1197.2 | 120466.3 | 26.7 | -17.2 | 4.2 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 44.9 | -1.6 |
| Cipla Ltd. | 1465 | 118350.5 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
Aptus Pharma INFORMATION ON IPO ISSUE
About Aptus Pharma
Aptus Pharma was incorporated on August 12, 2010. The company is engaged in marketing and distribution of finished pharmaceutical formulations through a contract manufacturing model. With agreements across seven manufacturing units, it offers a wide range of products across multiple therapeutic categories in diverse dosage forms
Object of the Issue
- Capital expenditure for office premises with furniture and industrial racks
- Working capital
- General corporate purposes
Aptus Pharma - PROMOTERS
| Name |
|---|
| Tejash Maheshchandra Hathi |
| Kapilbhai Hasmukhbhai Chandarana |
| Ghanshyam Vinubhai Pansuriya |
| Mohini Hardikbhai Gandhi |
Aptus Pharma - MANAGEMENT & LEADERSHIP
| Name | Designation |
|---|---|
| Tejash Maheshchandra Hathi | Managing Director |
| Chetan Shantilal Lalseta | Non-Executive Director |
| Jyotiben Hasmukhbhai Chandarana | Non-Executive Director |
| Riddhish Natwarlal Tanna | Non-Executive Director |
| Vikas Rambhai Jobanputra | Independent Director |
| Sejal Harit Palan | Independent Director |
Aptus Pharma Book Running Lead Manager
Interactive Financial Services Limited
mbd@ifinservices.in
Aptus Pharma Registrar to the issue
Bigshare Services Private Limited
ipo@bigshareonline.com
Aptus Pharma Strengths
Diversified product portfolio
The company’s diversified portfolio of over 194 pharmaceutical formulations across 11+ therapeutic segments drives market resilience and broad customer reach. Its offerings span categories such as anti-infectives, gastrointestinal, respiratory, cardiovascular, anti-diabetic, and general wellness, positioning it as a comprehensive solution provider in the pharmaceutical sector
Manufacturing alliance
The company maintains strong, long-term alliances with third-party manufacturers in Gujarat, Uttarakhand, and Himachal Pradesh, supporting its asset-light business model. Partners are selected through rigorous due diligence and regularly audited to ensure quality, compliance, and timely delivery
Quality standards
Quality is central to the company’s operations, embedded across every stage of the product lifecycle. All pharmaceutical batches undergo rigorous WHO-GMP-aligned testing, including assays, dissolution, stability, and content uniformity, often validated by accredited laboratories
Aptus Pharma Risks
Licenses & approvals
The company must obtain and maintain key statutory and regulatory permits to operate. Failure to secure or renew these approvals on time could disrupt operations and adversely affect results
Dependent on medical practitioners
The company relies heavily on medical practitioners, chemists, and pharmacies for product reach. Any disruption in these relationships could negatively impact business operations
Capital intensive
The company’s business is working capital-intensive, requiring significant stock maintenance for manufacturing. Inability to secure adequate borrowing for working capital needs could adversely impact operations and results
IPO FAQs
Aptus Pharma Ltd. IPO listing opened at Rs 80.80 while the issue price was Rs 70.00 giving 15.43% returns. After adjusting for subsequent bonus and splits, the stock trades at Rs 28.00 giving 840.89% gains since its IPO listing.
The promoters of the company are Tejash Maheshchandra Hathi, Kapilbhai Hasmukhbhai Chandarana, Ghanshyam Vinubhai Pansuriya and Mohini Hardikbhai Gandhi.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 65.0 - 70.0.
The IPO application opens on Sep 23, 2025 and closes on Sep 25, 2025.
The minimum lot size for the IPO is 4000. The maximum lot size for the IPO is 4000.
For all category investors, the minimum application amount for this IPO is Rs. 260,000.0, the maximum value for this IPO is Rs 280,000.0.
This IPO will be allotted on Sep 26, 2025.
The refund will be credited to your account on Sep 29, 2025.
The allotted shares will be credited to your demat on Sep 29, 2025.
Aptus Pharma Ltd.’s shares listed on the stock exchanges on Sep 30, 2025.